Association between kinetic of anti-neutrophil cytoplasmic antibody (ANCA), renal survival and relapse risk in ANCA glomerulonephritis

• Published in: Nephrology, dialysis, transplantation dialysis, transplantation, 2023-05, Vol.38 (5), p.1192-1203
• Main Authors: Samoreau, Clément, Piccoli, Giorgina Barbara, Martin, Cécile, Gatault, Philippe, Vinatier, Emeline, Bridoux, Frank, Riou, Jérémie, Desouche, Alice, Jourdain, Pierre, Coindre, Jean-Philippe, Wacrenier, Samuel, Guibert, Fanny, Henry, Nicolas, Blanchet, Odile, Croué, Anne, Djema, Assia, Pouteau, Lise-Marie, Copin, Marie-Christine, Beauvillain, Céline, Subra, Jean-François, Augusto, Jean-François, Brilland, Benoit
• Format: Article
• Language: English
• Subjects: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - complications; Antibodies, Antineutrophil Cytoplasmic; Chronic Disease; Glomerulonephritis; Humans; Kidney; Myeloblastin; Peroxidase; Retrospective Studies
• ISSN: 0931-0509; 1460-2385
• DOI: 10.1093/ndt/gfac240

ABSTRACT Background Anti-neutrophil cytoplasmic antibody (ANCA) kinetic in ANCA-associated vasculitis with glomerulonephritis (AAV-GN) has been suggested to be associated with AAV relapse. Few studies have focused on its association with renal prognosis. Thus we aimed to investigate the relationship between ANCA specificity and the evolutive profile and renal outcomes. Methods This multicentric retrospective study included patients diagnosed with ANCA-GN since 1 January 2000. Patients without ANCA at diagnosis and with fewer than three ANCA determinations during follow-up were excluded. We analysed estimated glomerular filtration rate (eGFR) variation, renal-free survival and relapse-free survival according to three ANCA profiles (negative, recurrent and persistent) and to ANCA specificity [myeloperoxidase (MPO) or proteinase 3 (PR3)]. Results Over a follow-up of 56 months [interquartile range (IQR) 34–101], a median of 19 (IQR 13–25) ANCA determinations were performed for the 134 included patients. Patients with a recurrent/persistent ANCA profile had a lower relapse-free survival (P = .019) and tended to have a lower renal survival (P = .053) compared with those with a negative ANCA profile. Patients with a recurrent/persistent MPO-ANCA profile had the shortest renal survival (P = .015) and those with a recurrent/persistent PR3-ANCA profile had the worst relapse-free survival (P = .013) compared with other profiles. The negative ANCA profile was associated with a greater eGFR recovery. In multivariate regression analysis, it was an independent predictor of a 2-fold increase in eGFR at 2 years [odds ratio 6.79 (95% confidence interval 1.78–31.4), P = .008]). Conclusion ANCA kinetic after an ANCA-GN diagnosis is associated with outcomes. MPO-ANCA recurrence/persistence identifies patients with a lower potential of renal recovery and a higher risk of kidney failure, while PR3-ANCA recurrence/persistence identifies patients with a greater relapse risk. Thus ANCA kinetics may help identify patients with a smouldering disease. Graphical Abstract Graphical Abstract